The <scp>BCL</scp>2 antagonist <scp>ABT</scp>‐199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in <i><scp>CXCR</scp>4</i><sup><i>Wild‐type</i></sup> and <i><scp>CXCR</scp>4</i><scp><sup><i>WHIM</i></sup></scp> mutated Waldenstrom macroglobulinaemia cells
Yang Cao(Nanjing Tech University), Steven P. Treon(Dana-Farber Cancer Institute), Jorge J. Castillo(Dana-Farber Cancer Institute), Zachary R. Hunter(Harvard University), Evdoxia Hatjiharissi(Boston University), Xia Liu(Harvard University), Matthew S. Davids(Dana-Farber Cancer Institute), Nickolas Tsakmaklis(Dana-Farber Cancer Institute), Guang Yang(Blueprint Medicines (United States)), Jie Chen(Zhejiang Chinese Medical University), Lian Xu(Huazhong Agricultural University), Sandra Kanan(University of Washington Medical Center)
Cited by 71
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752